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Basic research in sarcoma models has been fundamental in the discovery of scientiﬁc milestones leading to a better understanding
of the molecular biology of cancer. Yet, clinical research in sarcoma has lagged behind other cancers because of the multiple clinical
and pathological entities that characterize sarcomas and their rarity. Sarcomas encompass a very heterogeneous group of tumors
with diverse pathological and clinical overlapping characteristics. Molecular testing has been fundamental in the identiﬁcation
and better deﬁnition of more speciﬁc entities among this vast array of malignancies. A group of sarcomas are distinguished by
speciﬁc molecular aberrations such as somatic mutations, intergene deletions, gene ampliﬁcations, reciprocal translocations, and
complex karyotypes. These and other discoveries have led to a better understanding of the growth signals and the molecular
pathways involved in the development of these tumors. These ﬁndings are leading to treatment strategies currently under intense
investigation. Disruption of the growth signals is being targeted with antagonistic antibodies, tyrosine kinase inhibitors, and
inhibitors of several downstream molecules in diverse molecular pathways. Preliminary clinical trials, supported by solid basic
research and strong preclinical evidence, promises a new era in the clinical management of these broad spectrum of malignant
tumors.
1.Introduction
Remarkable gains in the understanding of cancer biology
have been attained in the past two decades. Novel method-
ologies and laboratory techniques have allowed molecular
dissection of cancer cells leading to a more precise portrait of
tumorigenesis. The biological and molecular characteristics
of transformed cells that produce and sustain malignant
growth have been organized in a coherent and compre-
hensive manner by Hanahan and Weinberg [1]. Sustained
growth, evasion of growth suppressors, resistance to death,
induction of angiogenesis, and the ability to invade and
spread are fundamental tumor characteristics, all of which
have underlying molecular correlates that scientists are
beginning to unravel and understand. More recently, other
enabling characteristics have supplemented these initial
concepts, namely, avoidance of immune destruction, tumor-
promoting inﬂammation, deregulation of cellular energy
pathways, and genomic instability [1].
Although these principles are applicable to all malignan-
cies,individualclassesoftumorsandevenindividualpatients
diﬀer in the particular speciﬁcities of the complex process
of malignant growth. Further, this is a multistep dynamic
process subject to change and adaptation over the course of
the disease, from premalignant lesions to metastatic spread.
Sarcoma research has lagged behind other cancers
becauseoftherarityofthesetumorsandthemultipleclinical
and pathological entities that compose these malignancies.
Yet, research work with sarcomas has been central in
elucidating many of the modern concepts of cancer biology
including the molecular signals driving tumor growth and
permanence. Even though few advances in the treatment of2 Sarcoma
thesehighlyresistanttumorshaveoccurred,somemilestones
have been carved based on clinical and bench research in
sarcoma.Thispaperhighlightssomeofthemostoutstanding
workinthepast,currentknowledgeofthemolecularbiology
of sarcomas and the challenges to control or cure these rare,
heterogeneous malignancies.
1.1. The Rous Sarcoma Virus. The seminal paper by Rous
describing the ability to transfer an avian spindle cell
sarcoma from one Plymouth Rock hen to another was
largely dismissed as irrelevant to human disease [2]. Rous
described experiments that eventually led to our modern
understanding of the genesis of cancer. Later, Rous published
work describing the transmission of sarcoma using tumor
cell-free extracts indicating that a biological agent on the
ﬁltrate could cause tumor growth and could be propagated
throughsubsequentpassages.Theseobservationsopenedthe
ﬁeld of tumor virology and would link sarcoma research
intimately to the ﬁeld of cancer research.
The agent responsible for this unprecedented discovery
was a retrovirus (Rous sarcoma virus (RSV)). A cadre of
researchers began to unravel the mystery of this ﬁnding over
the years. Remarkably, it took more than 50 years from the
initial report for the world to realize the magnitude of the
discoverywhentheexistenceofageneticsequenceintheRVS
capable of inducing transformation, the src gene was dis-
covered. The src-encoded tyrosine kinase (TK) was the ﬁrst
evidenceofTKactivityinvolvedinmalignanttransformation
[3], and it was the ﬁrst to demonstrate that activation occurs
by phosphorylation of the aminoacid tyrosine in host cell
proteins. These enzymes have been shown to be essential for
the malignant transformation of cells by oncogenic signals
[4]. Steadily the functional relationship between oncogenic
protein activity and receptor signaling began to emerge into
a cohesive model that occupies much of the current research
in carcinogenesis and biology of cancer cells. The eventual
development of targeted therapies, interfering with these
molecular pathways saw the dawn of a modern approach to
cancer therapy.
The viral etiology of cancer in vertebrates evolved
from these observations [5]. Viral particles were described
in multiple vertebrate species and culminated with the
identiﬁcation of the ﬁrst retroviral oncogene named “v-src”
and its cellular homologue (c-src). It was realized that the
viral oncogenes derived from functional cellular genes (pro-
tooncogenes) capable of inducing malignant transformation
upon activation [6]. Subsequent years saw the identiﬁcation
of a number oncogenes and tumor-suppressor genes that
were altered in human cancer. The concept of clonal
evolution and a molecular model of multistep tumorigenesis
evolved from these discoveries [7].
1.2. RAS and Human Oncogenes. As the concept that cancer
was a disease of altered genes gained momentum, research
with other animal sarcoma-inducing viruses led to further
remarkable discoveries. The viruses that stand out were the
rat sarcoma virus from the 1960s. The ras genes from the
Kirsten sarcoma virus (KRAS), the Harvey sarcoma virus
(HRAS), and later NRAS were shown to encode highly
related proteins (H-Ras, N-Ras, K-Ras4A, and K-Ras4B) [8].
Later on, the cellular homologous of KRAS was found in
human cancer cells (1982). A single aminoacid mutation was
proven to allow the constitutive activation of the oncogene.
Thus, the concept of cellular oncogenes capable of inducing
human cancer was conﬁrmed by the cloning of c-RAS the
ﬁrst human oncogene. The Ras proteins were later found
to be GTPases involved in cellular signal transduction for
cell growth and division. Activating mutations in Ras have
been described in 20–25% of all human tumors and much
higher in some speciﬁc tumor types [9]. During the 1990s
the role of KRAS in tumorigenesis was established and the
molecular signaling pathways involved in this process began
to be unraveled [10].
Enormous scientiﬁc gains in the understanding of
human cancer derived from the study of these viral agents.
These discoveries, derived from the study of sarcomas, will
remain engrained in the annals of history of cancer.
1.3. Coley’s Vaccine. The ﬁrst systematic study of immun-
otherapy for the treatment of malignant tumors began in
1891 by William Coley. Following the clinical observation
of a dramatic response of one young patient to an injection
of streptococcal organisms Coley treated, amidst much crit-
icism and controversy, hundreds of patients with soft-tissue
and bone sarcomas over a span of four decades [11]. Later
he would use heat-killed streptococcal organism and Bacillus
prodigiosus (Serratia marcescens), a concoction that became
known as Coley’s Toxin. By 1920 his work would become of
ill repute. The Bone Sarcoma Registry (the ﬁrst established
cancer registry) declared lack of suﬃcient evidence of the
therapeutic beneﬁt claimed by Coley. Regardless of the
longlasting debate surrounding his work, Coley’s research
would set the foundations on cancer immunotherapy. The
scientiﬁc interest on this approach will rapidly grow as
the biology of the immune system was progressively better
understood. We could now assume that the eﬀects of the
Coley’s toxins were mediated by activation of the immune
system, with ensuing cellular activation and production of
powerful cytokines (e.g., interleukins, interferons, tumor
necrosisfactor,etc.),someofwhichwouldbecometherapeu-
tic tools in contemporary cancer immunotherapy.
1.4. Sarcomas and Interferon. The discovery of interferon
was dismissed as a laboratory curiosity until Gresser showed
that human leukocytes produced substantial amounts of
these cytokines and later described an antiproliferative
eﬀect on cultured cells and animals [12]. Immunomod-
ulating properties were also ascribed to interferon (IFN)
and triggered enormous interest to investigate IFN as a
potential anticancer agent, amidst the growing evidence
of the existence of cancer-inducing transforming viruses.
Strander pioneered the initial clinical use of IFN in human
cancer. His group showed in vitro evidence of the activity
of IFN in osteosarcoma (OS) cells and in human sarcoma
tumorstransplantedintomicewhichledtostudiesusingIFN
treatment in OS after surgery [13]. At a decade of followup,Sarcoma 3
Table 1: HHV-8 Genes and role in Kaposi Sarcoma.
Latent genes Eﬀects Other properties
V-cyclin (ORF 72)
Constitutively activates CDK6
Interferes with cyclin-dependent cell cycle arrest
Bypasses inhibitory controllers of cell cycle
regulation (p16, p21, and p27)
Phosphorylates pRb;
Releases E2F
Activates S-phase genes
v-FLIP (ORF 71) Competes with proapoptotic signals mediated
via FAS-FADD Oncogenic
LANA (ORF 73)
B l o c k st u m o rs u p p r e s s o rg e n e sp 5 3
Competes with E2F transcription factor for
binding to pRb
Controls genes triggering the switch to lytic phase
Oncogenic
Kaposin (K12) Upregulates PORX1; induces reprogramming of
vascular endothelial cells Oncogenic
K10.1 (LANA-2) Blocks IFN- and IRF-mediated transcriptional
activation; binds p53?
Lytic genes Eﬀects Other properties
vIL-6 (ORF K2)
Activates gp130 independently of IL-6R
Activates NFκB; constitutively activates GPCR.
Activates JAK1 and STAT 1/3 pathways
Induces transcription of VEGF and MMP-9
Autocrine and paracrine loops
Oncogenic
vGPCR (ORF 74) Constitutively activate GPCRs; binds IL-8 Oncogenic
Angiogenic
vMIP-I and vMIP-II (ORF K4) CCR-3 and 4 agonist
Broad spectrum cytokine receptor antagonist.
Entry coreceptor for HIV-1
Angiogenic
vBcl2 (ORF 16) Antiapoptotic activity
Inhibits bax Oncogenic
sarcoma-speciﬁc survival was 38% for the patients treated
before 1985 and 63% for the group treated with higher
total IFN dose afterwards. Because of the uncontrolled study
design, there is no way to conﬁrm a direct clinical beneﬁt
from IFN therapy in this pioneering study. Yet, continuous
interest remains in exploring the potential beneﬁt of IFN
in OS, and a prospective randomized trial was launched
by the European and American Osteosarcoma Study Group
(EURAMOS 1) using pegylated IFN. We know now that IFN
is an endogenous antiangiogenic regulator. IFN-α mediates
cellular signaling via the JAK/STAT cascade with complex
interaction with other signaling pathways including MAPK,
PI3K, mTOR, and IFN-induced apoptosis via activation of
Bak and Bax and the mitochondrial pathway. All of these
molecular cascades are seemingly necessary in generating an
IFN response [14, 15].
1.5. Kaposi’s Sarcoma: A Model of Viral Carcinogenesis.
Kaposi’s sarcoma (KS) was originally described in 1872
and for decades remained as an uncommon low-grade,
slow-growing tumor aﬀecting predominantly patients of
Jewish and Mediterranean origin (“Classsic” KS). In the
1950s, an endemic type of KS was identiﬁed in equatorial
Africa regions with some patients exhibiting rapid and
aggressive course and high mortality. Epidemiological data
from this endemic form raised suspicion of a viral etiology
in association with increased relevance of oncogenic viruses
in other malignancies [16].
Renewed eﬀo r t st oi d e n t i f yt h ec a u s eo fK Sc a m ea sa
result of the high incidence of KS in patients with AIDS.
Epidemiological data led to the proposal that a sexually
transmitted agent was responsible for KS [17]. Distinct DNA
fragments of a herpes virus from KS were ﬁrst isolated in
1994 [18] .T h en e wv i r u sw a sf o u n dt ob eag a m m ah e r p e s
virus and was designated HHV-8. HHV-8 DNA is found
in over 90% of specimens from classic KS, endemic KS,
posttransplant KS, and epidemic KS.
Expression of multiple cellular-derived oncogenes has
been identiﬁed by genetic dissection of the HHV-8 during
i t sl a t e n ta n dl y t i cp h a s e s[ 19, 20]. KS lesions contain
predominantly HHV-8 in latent phase. In these cells, HHV-
8 expresses a limited number of “latent” genes (Table 1).
The lytic phase of HHV-8 is more closely implicated in the
development of KS and its ability to spread from lymphoid
tissuetoendothelialcells.Theswitchtothelyticphaseresults
in the expression of a number of virally encoded cellular
homologues (Table 1). The gene expression during the lytic
phase is initiated by the HHV-8 replication transactivation
activator gene (ORF 50; RTA), which is under regulatory
controlbyLANA-1.RTAactivatesDNAandproteinsynthesis
resulting in replication and assembly of new infective viral
particles [19]. Lastly, the role of HIV virus in AIDS-related
KS has been studied and suggests a synergistic eﬀect with
HHV-8inthegenesisofthetumorinthesepatients.TheHIV
Tat protein has been shown to compete with heparin sulfate
proteoglycans, which bind β-ﬁbroblast growth factor (β-
FGF), increasing free levels of this angiogenic factor. KS has
been described as an angiogenic neoplasm, and the genetic
proﬁle of the spindle cells, a major cellular component of KS
lesions,closelyresembleslymphaticendothelium[21].These4 Sarcoma
endothelial cells are responsive to angiogenic growth factors.
Second, HIV Tat activates HHV-8 increasing expression of
several early viral genes (Table 2).
IFN was shown to produce antitumor eﬀects in AIDS
patients with KS [22, 23] leading to the FDA approval of IFN
fortreatmentofAIDS-associatedKSin1988.However,itwas
thecontrolofHIVreplicationwithhighlyantiviralantiretro-
viral therapies (HAART) combinations that resulted in a
signiﬁcant decline in the incidence of KS in AIDS patients.
Whether this was the result of suppression of HIV-Tat (or
other HIV genes) or the partially restoration of immunity,
this epidemiological shift reinforces the participatory role of
HIV in the tumorigenesis of KS.
KS stands out as one bona ﬁde example of viral carcino-
genesis in man. Although many factors are required for the
malignant transformation to occur, HHV-8 is the primary
trigger of a cascade of molecular events that lead to the
development of this unique type of sarcoma.
1.6. Gastrointestinal Stromal Tumors (GISTs). The term
“gastrointestinal stromal tumors” (GIST) refers to mes-
enchymal tumors of the gastrointestinal tract with features
of neurogenic or myogenic diﬀerentiation but neither of
neurogenic (S100-protein negative) or of smooth muscle
origin (absence of myoﬁlaments). Somatic mutations of
c-KIT are involved in the genesis of these tumors. The
transforming viral gene, Hardy-Zuckerman 4 feline sarcoma
virus (v-KIT; HZ4-FeSV), was discovered in 1983 in feline
sarcomas [24]. The c-KIT gene is the cellular homologue of
a v-KIT that encodes a TK growth factor receptor (CD 117)
and has been associated with growth and diﬀerentiation of
immature cells [25]. The CD117 receptor is expressed by
the interstitial cells of Cajal (ICC) and by neoplastic cells
most notably by GIST [26]. From these observations, it was
concluded that the ICC was most likely the cell of origin
of GIST. The binding of the ligand Steel factor (SLF), or
stem-cell factor to CD117 results in activation of KIT TK
and its downstream substrates, which serve as eﬀectors of
signal transduction. Mutations of c-KIT resulted in gain of
function of the KIT TK and constitutive activation of its
molecular downstream pathways, predominantly the PI3K
pathway [27, 28].
Approximately 75–85% of GIST patients express acti-
vating mutations of KIT of which exon 11 is the most
common (57–70%), followed by exon 9 (5–18%) and rarely
exon 13 and 17 domains (<2%). Only 5% of patients
exhibit mutations in PDGFR and some patients exhibit
neither KIT nor PDGFR (10–15%) [29]. Work with a c-
KIT expressing human myeloid leukemia cell line proved
that STI 571 (imatinib mesylate) was able to block c-KIT
autophosphorylation [30]. Shortly after, a human GIST
cell line expressing an active KIT mutation was completely
inhibited by imatinib [31]. These ﬁndings translated into the
ﬁrst report on the clinical eﬃcacy of imatinib in a single
patient with GIST [32] which was followed by an auspicious
phase II trial [33]a n daf a s tt r a c kF D Aa p p r o v a l .T h u s ,G I S T
became the ﬁrst solid tumor, where therapeutic interference
of a mutated TK mutation showed clear beneﬁt.
Table 2: HIV and Kaposi Sarcoma. HHV-8 genes activated by HIV-
Tat.
HHV-8 genes Eﬀects Other properties
vGPCR (ORF 74)
Constitutively activates
GPCR
Promotes synthesis of
VEGF
Oncogenic
Angiogenic
vBcI2 (ORF 16) Antiapoptotic activity
Inhibits bax Oncogenic
vIRF-1 (ORF K9)
Interferon regulatory
factor homolog
Activates the c-myc
oncogene
Antagonizes
IFN-mediated
antiviral
immunity
Later work demonstrated that the speciﬁc location and
nature of the activating mutation on KIT inﬂuences the
clinical behavior of GIST. Most nonresponsive patients and
almost all patients with early relapses were shown to carry
an exon 9 KIT, PDGFR mutations or a wild type. Although
KIT exon 11missense mutations are foundpredominantly in
lower-grade, favorable-outcome, GIST mutations involving
deletion or duplication of multiple aminoacids in exon 11
have been related to poorer outcome [34]. Imatinib resis-
tance has been related to survival pathways that circumvent
KITblockadelinkedtosecondarymutationsinKITexons13,
14, 17, or 18 which typically develop in tumors with primary
exon 11 mutations leading to late progression in 50 to 70%
of the patients [35].
Sunitinib, a multifunctional TK inhibitor, produces
responses in patients with relapsing or resistant to imatinib
[29]. In vitro inhibition of PI3K pathway in imatinib
resistant cells arrests cell growth and induces apoptosis
[35], suggesting that this may be a mechanism of action of
sunitinib in imatinib-resistant patients. These observations
are important as they relate to the fact that even speciﬁc
targeted molecular therapies are not infallible or permanent
and extensive further work lies ahead.
2. Molecular Biology of Sarcomas
The molecular ﬁndings in KS and GIST paved the way
to an intensive search for molecular targets with a clini-
cal translational potential. Bone and soft-tissue sarcomas
encompass a very heterogeneous group of tumors with
diverse pathological and clinical overlapping characteristics.
Histomorphology distinguishes pleomorphic and nonpleo-
morphic tumors and spindle cell, epitheloid and small
blue round cell tumors. With immunohistochemistry some
tumors can be identiﬁed with epithelial or mesothelial line
ofdiﬀerentiation.Theadventofmoleculartestinghasfurther
assisted in the identiﬁcation of more speciﬁc entities among
this vast array of malignancies.
At a molecular level, a group of sarcomas are distin-
guished by speciﬁc molecular aberrations including somatic
mutations, intergene deletions, gene ampliﬁcations, and
reciprocal translocations. Others carry complex karyotypesSarcoma 5
Table 3: Reciprocal translocations in sarcomas.
Tumor EWS translocations Fused genes Incidence (%)
Ewing sarcoma/PNET
t(11;22)(q24;q12)
t(21;22)(q22;q12)
t(7;22)(p24;q12)
t(17;22)(q12;q12)
t(2;22)(q33;q12)
EWS-Fli1
EWS-ERG
EWS-ETV1
EWS-E1AF
EWS-FEV
85
10
Rare
Rare
Rare
Desmoplastic small round cell tumors t(11;22)(q13;q12) EWS-WT1 75
Myxoid liposarcoma t(12;22)(q13;q12) EWS-CHOP 5
Clear cell sarcoma t(12;22)(q13;q12) EWS-ATF1 >90
Myxoid liposarcoma t(12;16)(q13;q11) FUS-CHOP 95
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q11)
t(9;17)(q22;q11)
EWS-CHN
RBP56-CHN
75
20
Tumor Non-EWS Translocations Fused genes Incidence (%)
Synovial sarcoma t(X;22)(p11.23;q11)
t(X;18)(p11.21;q11)
SYT-SSX1
SYT-SSX2
65
35
Alveolar Rhabdomyosarcoma t(2;23)(q35;q14)
t(1;13)(q36;q14)
PAX3-FKHR
PAX7-FKHR
75
10
Congenital ﬁbrosarcoma t(12;15)(q13;q25) ETV6-NRTK3 Unknown
Alveolar sort part sarcoma t(X;17)(p11;q25) ASPSCR1-TFE3 99
and nonspeciﬁc genetic alterations. The majority of high-
grade sarcomas with complex karyotypes have a high fre-
quencyofprotein53(p53)andretinoblastomaprotein(pRb)
mutations as well as impairments in DNA repair and severe
chromosomal instability, but no speciﬁc genetic alterations
[36–40].
Thesemolecularaberrationshaveundoubtedlyimproved
the diagnostic capabilities to conﬁrm the nature of many
STS. However, the predictive and prognostic signiﬁcance of
these anomalies is hampered by the lack of standardization
of methodologies and the small sampling amongst many of
the several subtypes of sarcomas. Early reports that associate
molecular abnormalities in ES and SS with prediction of
outcome have been disputed in larger studies [41, 42].
2.1. Somatic Mutations. The gain-of-function KIT and
PDGFR gene mutations in GIST are the most notable
examples of this type of genetic abnormality in soft-tissue
sarcomas.
2.2. Intergene Deletions. Rhabdoid tumors, which are highly
aggressive and carry a poor prognosis, show partial or com-
plete loss of the hSNF5/INI1 gene (chromosome 22q11.2).
This gene is a core member of the SWI/SNF chromatin
remodeling complex, and its loss leads to cell cycle progres-
sion. This abnormality is also present in 50% of malignant
peripheral nerve sheath tumors and epithelioid sarcomas
[37].
2.3. Ampliﬁcations. Ampliﬁcations of genomic regions are
not speciﬁc for a given sarcoma subtype, but ampliﬁcation
of the murine double minute gene (MDM2) and the cyclin-
dependent kinase 4 (CDK4) at chromosome 12q13–15 are
highly characteristic in dediﬀerentiated liposarcomas (LPS)
[40].
2.4. Reciprocal Translocations. Numerous translocations
have been described in the past two decades that deﬁne
15–20% of sarcomas (Table 3). The ﬁrst translocation
identiﬁed in patients with Ewing sarcoma (ES) between
the EWSR1 gene on chromosome 22q12 and FLI1 (Friend
leukemia virus integration 1), a member of the ETS gene
family of transcription factors on chromosome 11q24, was
reported in 1992 [41]. This remains the most frequent
abnormality, present in 85% of the patients. Other less
frequent translocations have been described with other
members of the ETS gene family. These translocations
deﬁned the ES family of tumors including the peripheral
primitive neuroectodermal tumors (PNET) and became a
critical diagnostic tool and a window to the pathogenesis of
these and other sarcomas. The translocated genes give origin
to a chimeric fusion gene encoding an aberrant transcription
factor which alters several cell signaling pathways aﬀecting
proliferation and apoptosis leading to invasiveness and
metastasis [43].
Several fusion proteins have been described resulting
from translocations that involve the EWS family of genes
and the ETS family in various types of sarcomas. ES includes
fusion genes between EWS and FLI1 (85%) and ERG (10%)
and rare cases involving ETV1, ETV4, FEV, and other ETS
genes. Other gene products with a high homology to EWS
can replace EWS in diﬀerent fusions including CHN (or
NOR1)inextraskeletalmyxoidchondrosarcomasandCHOP
(or CEBPE) in a proportion of myxoid LPS [38–40].
A second group of fusion genes are formed by non-
EWS translocations and have been described in various
types of sarcomas notably synovial sarcoma (SS), alveolar,
rhabdomyosarcoma (ARMS), and myxoid LPS (Table 3).6 Sarcoma
Table 4: The IGF System in sarcoma pathogenesis.
Tumor Abnormal genes Involved ligand Involved receptor Other properties
Ewing sarcoma/PNET EWS-FLI1 IGF-1 IGF-1R Downregulates IGFBP-3
Synovial sarcoma SYT-SSX1/SYT-SSX2 IGF-2 IGF-1R
Alveolar rhabdomyosarcoma PAX3-FKHR/PAX7-FKHR IGF-2 IGF-1R Autocrine loop
Desmoplastic small round cell tumors EWS-WT1 ? IGF-1R
Congenital ﬁbrosarcoma ETV6-NTRK3 IGF-2 IGF-1R
Embryonal rhabdomyosarcoma LOH 11p15.5 pften IGF-2 IGF-1R Autocrine loop
Leiomyosarcoma Complex karyotypes IGF-2 IGF-1R PI3K highly activated
Osteosarcoma Complex karyotypes IGF-1, IGF-2 IGF-1R
Kaposi sarcoma Complex karyotypes ? IGF-1R, IR-A
GIST Lacking KIT, PDHFR mutations IGF-1, IGF-2 IGF-1R Poorer Prognosis
These translocations have a tight speciﬁcity for a partic-
ular cell type. Gene fusions seem to only occur in susceptible
cells at a given stage of development. Those cells surviving
the abnormal translocation will eventually suﬀer malignant
transformation. Accordingly, these fusion genes and their
transcriptional targets may deﬁne the tissue lineage where
thetumororiginates,thephenotypeofthetransformedcells,
and perhaps the clinical course of each subtype of sarcoma.
ES is a striking example of lineage speciﬁcity [44].
The fusion genes are believed to promote carcinogenesis
via stimulation or suppression of other genes involved in
cell proliferation (i.e., upregulation of PDGF-C, CCDN1,
and c-MYC), evasion of growth inhibition (via downreg-
ulation of CDK inhibitors and TGF-β receptor), escape
from senescence by upregulation of hTERT, escape from
apoptosis by repression of IGFBP-3 promoter, induction of
angiogenesis by increasing VEGF and promoting invasion
andmetastasesviamatrixmetalloproteinases(MMPs).Some
fusion genes perform as autocrine stimulation loops. In der-
matoﬁbrosarcoma protuberans (DFSP), the growth factor
platelet-derived growth factor B (PDGFB) is constitutively
activatedbythecollagen,typeI,alpha1(COL1A1)promoter
in chromosome 17. In congenital ﬁbrosarcoma the ETV6-
NTRK3 fusion product (t(12; 15)(p13; q25)) results in
constitutive activation of Ras/MAPK mitogenic pathway and
PI3K/Akt pathway-mediated cell survival via the insulin-like
growth factor 1 receptor [45, 46].
Overlapping of these groups is exempliﬁed by clear
cell sarcoma (CCS) and alveolar soft part sarcoma (ASPS)
which are biologically linked by a common mechanism
that upregulates expression of c-Met and tumorigenesis.
These seemingly unrelated tumors dysregulate the MiT
family of transcription factors and are referred as “MiT
tumors” because of the involvement of the microphthalmia-
associated transcription factor (MIFT) in their pathogenesis.
In CSS the t(12; 22)(q13; q12) translocation fuses the
EWS-ATF1 and constitutively activates AFT turning on
several genes including MIFT [47]. ASPS is characterized
by a non-EWS translocation between the ASPL locus on
chromosome 17 and the TFE3 locus on the X chromosome
(der(17)t(X; 17)(p11q25)) [48]. MITF, TFE3, TFEB, and
TFEC comprise a family of transcription factors that share a
highly homologous DNA binding and dimerization domain.
These proteins bind identical DNA elements, suggesting that
they may activate common downstream targets [49].
2.5. The Insulin-Like Growth Factor System (IGF). The role
of this pathway has been recognized as one of the major
signaling pathways in the tumorigenesis of several sarcomas.
TheIGFconsistsof3mainligands:IGF-I,IGF-II,andinsulin
which bind to four types of membrane receptors, namely,
IGF-1R, igf-2R, the insulin receptor (IR), and hybrid recep-
tors. IGF-1R and Insulin receptors are 84% homologous and
interact with each other to form heterodimers with high
aﬃnity to their ligands. In addition, there are IGF circulating
binding proteins (IGFBP) that modulate the availability of
the free ligands to the receptors. The concentration of the
ligands and the binding proteins are under the inﬂuence
of growth hormone and liver synthesis. The binding of
ligand and receptor activates intracellular signaling cascades
via the PI3K and MAPK pathways. Abnormalities among
or along these numerous molecules have been described in
diﬀerent human malignancies and particularly in sarcomas
[50, 51].
Several sarcoma fusion genes and other molecular
anomalies have been shown to upregulate ligand (IGF-
1o rI G F - 2 )o rr e c e p t o r( I G F - 1 R )e x p r e s s i o na n d ,i nE S ,
to downregulation of IGFBP-3 (Table 4)T h eI G Fs y s t e m ,
particularly the IGF-1R, has been validated both in vitro
and in experimental animal models as a central participant
in the induction of malignant transformation in ES, RMS,
leiomyosarcoma (LMS), and other sarcomas. Furthermore,
preliminary clinical observations have related markers of the
IGF system to tumor behavior and prognosis [51].
2.6. The PI3K Pathway. Heightened expression of IGF-1R
has been related to loss of transcriptional repressors (p53)
or increase in transcriptional activators in various human
cancers. Upregulation of IGF-1R results in sustained activa-
tion of downstream PI3K and MAPK pathways (Figure 1).
The carcinogenic potential of abnormal or unregulated
PI3K/AKT or RAS/MAPK pathways’ signaling is related to
their regulatory role in cell cycle progression, cell growthSarcoma 7
IRS PI3K PDK1
PIP2 PIP3
eIF-4E eIF-48 rpS6
MYC CKD1
Cap-dependent
translation
Top-dependent
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Figure 1: Several growth factor signals activate cell membrane receptor tyrosine kinases leading to activation of downstream interacting
signal transduction pathways (PI3K/AKT, RAF/MAPK, and MTOR). Within the RAF/MAPK pathway, activated receptors lead to SHC-
mediated activation of RAS and propagation of signalling through RAF, MEK (a.k.a. MAP2K), and MAPK (a.k.a. ERK). Activated MAPK
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molecular “node” acting as a master switch, which triggers multiple downstream signaling pathways including mTOR pathway activation.
A key regulatory enzyme is PTEN that modulates PI3K and SHC phosphorylation. Activated AKT signals a number of mitogenic processes
promoting proliferation and increased cell survival, antiapoptotic signals, and upregulation of cell-cycle proteins (cyclin D1 and CDK4).
and proliferation, diﬀerentiation, and apoptosis [50, 51].
Activation of PI3K turns on AKT, key molecular “node” act-
ing as a master switch, which triggers multiple downstream
signaling pathways (including mTOR activation) promoting
proliferation and increased cell survival, antiapoptotic sig-
nals and upregulation of cell-cycle proteins (cyclin D1 and
CDK4). Recent experimental evidence supports the central
role of AKT in STS with complex karyotypes. In a mouse
model using and an adenovirus with Cre-recombinase
and conditional mutations of Kras and p53 over 90% of
the animals developed high grade sarcomas, resembling
malignant ﬁbrous histiocytoma (MFH) [52]. Another model
using mice genetically inactivated for pTEN (phosphatase
and tensin homolog) over 80% of the animals developed
abdominal LMS [53].
2.7. MAPK. Overexpression and activation of the MAPK
pathway (MKK) has been demonstrated in several epithelial
malignancies and related to tumor proliferation and metas-
tases. This pathway is coactivated by IRS system with PI3K
but its role in the genesis of sarcoma is less deﬁned. Growth
factor-induced activation of Ras leads to the activation
of Raf, followed by the activation of MAPK/ERK kinases
(MEK1-MEK2) and lastly the activation of ERK1 and ERK2
(Figure 1). The latter proteins regulate cell proliferation,
survival, diﬀerentiation, and migration. In one study, RAF1
and MEK 1/2 mRNA were detected in STS cell lines and
OS specimens and demonstrated dose- and time-dependent
inhibition of cell growth when treated with a MEK inhibitor
[54]. Similar observations have been reported in SS where
TK inhibition with sorafenib inhibited the MKK pathway,8 Sarcoma
downregulated cyclin D1 and pRb levels, caused G1 arrest,
and induced apoptosis [55]. In a xenograft model, MKK sig-
naling was necessary for tumor growth and vascularization
and treatment with anthrax lethal toxin (LeTx) produced
extensive tumor death and antiangiogenic eﬀects. LeTx
containslethalfactor(LF),azincmetalloproteasethatcleaves
and inactivates several MKK proteins, suggesting that MKK
hadapredominantlyproangiogeniceﬀectinthismodel[56].
2.8. The Role of mTOR Pathway. Activation of PI3K-AKT
is a convergence point of activation of growth factor
receptors driving the growth of various sarcomas (Figure 1).
Intrinsic activation of the mTOR pathway in sarcomas is the
result of abnormal signaling of these pathways [57]. Other
mechanisms explaining over activation of mTOR involve the
loss of regulatory inhibitory gene activity of the tuberous
sclerosis complex (TSC) proteins or PTEN inactivation
by methylation of the promoter, gene mutation, or allelic
deletions such as those reported in perivascular epithelioid
cell tumors (PEComas). Loss of LKB1 protein also leads to
hyper activation of mTOR signaling in a manner similar to
the loss of PTEN [58–60].
2.9. Angiogenesis. Angiogenesis is regulated by equilibrium
between proangiogenic (i.e., VEGF, FGF, EGF, PDGF, HIF)
and antiangiogenic factors (i.e., angiostatin, IFN, throm-
bospondin, and interleukins 1, 4, 12, 18, and 21) which are
produced by both the malignant cells and the microenviron-
ment including endothelial cells, ﬁbroblasts, and immune
cells. Vascular endothelial growth factor pathway plays a
dominant role in the pathogenesis and biology of STS.
VEGF is overexpressed in 25% of tumors, and high VEGF
is associated with an increased risk of metastases and
poorer prognosis. Strong VEGF expression is often present
in tumors rich in vasculature and epithelioid features
such as epithelioid sarcoma, KS, and ASPS. Serum VEGF
levels have been strongly correlated with tumor grade and
mass and usually poorly diﬀerentiated tumors. STS with
high VEGF expression are associated with resistance to
chemotherapy [61, 62]. As with IGF, the VEGF downstream
pathway involves PI3K and MAPK indicative of intermingle
of cell membrane signals. Distinct from these pathways
is the VEGF-induced activation of PGLG1 which exerts
proangiogenic eﬀects via protein kinase C (PKC) [61].
Other proangiogenic factors are upregulated in STS
including PDGFR, MMP-2, and Notch-1 and Notch-4, basic
FGF and angiopoietin-2 with certain variability according to
type and grade of the sarcoma. For instance, ﬁbrosarcoma
and LMS showed the highest bFGF levels [63]. Some
chromosomal translocations and their fusion proteins can
act as transcription factors for promoters of the VEGF gene
as is the case of the highly vascular ASPS. Similarly the
activationofmTORmaypromoteangiogenesisviacontrolof
the hypoxia inducible factor (HIF)-1α and mTOR inhibition
results in an antiangiogenic eﬀect [58].
2.10. Telomeres. Cell senescence has been considered a
hallmark of cancer and has been related to chromosomal
telomere maintenance mechanisms currently under scrutiny
in several malignancies. In a LPS model, using high-
resolution DNA mapping array, high level of genome insta-
bility and genetic ampliﬁcations were identiﬁed. In contrast
to most stem cells and other cancer cells, that use reverse
transcriptase telomerase for telomere maintenance, sarcoma
cells activate the alternative lengthening of telomeres (ALT)
mechanism as often as telomerase. ALT positive LPS have
higher genetic instability and a worse prognosis than non-
ALT tumors [64]. A genetic change, the deletion of chromo-
some 1q32.2-q44, is seemingly speciﬁc to the activation of
ALT mechanism in this model [65].
2.11. Hedgehog (Hh) Pathway. Activation of Hh pathway
results in stimulation of a wide range of prosurvival tran-
scription factor genes. Abnormal activation of Hh pathway
has been implicated in the genesis of various cancers
particularly basal cell carcinoma, medulloblastomas, and
RMS. Activation of Hh is manifested by the expression
of several proteins (Ptch1, Gli1, Gli3, and Myf5). These
markers are expressed by embryonal RMS and fusion gene-
negativealveolarRMS,whereasFOXO1-PAX3/PAX7positive
ARMS are not [64]. Preliminary observations have shown
augmented Hh signaling in cancer stem cells as well as in
stromal nonmalignant cells surrounding malignant tumors
and may constitute another cofactor in the genesis of
sarcomas and other cancers [66].
2.12. Cancer Stem Cells and Mesenchymal Cells in Sarcoma.
A growing body of evidence suggests the existence of
cancer stem cells (CSCs), pluripotential stem cells that can
perpetuate the generation or renewal of tumor forming cells
in solid tumors [67] .T h eﬁ r s te v i d e n c eo fc a n c e rs t e mc e l l s
in sarcoma was reported in 2009. Using surgically resected
ES primary tumors, a population of CD133 positive cells
fulﬁlling in vitro and in vivo criteria of CSC was identiﬁed.
These criteria included the capacity to generate and sustain
tumor growth in a xenograft model and to diﬀerentiate,
in vitro, along adipogenic, osteogenic, and chondrogenic
lineages [68]. These data are supportive of the mesenchymal
stem cell (MSC) origin of ES. Thus, ES-initiating cells seem
to conserve the properties of their putative cell precursors.
In this model, the expression of the EWS-FLI-1 fusion
proteininMSCcellswassuﬃcienttodevelopES-liketumors.
Lastly, the CD133+ CSC studied showed signiﬁcantly higher
expression of OCT4 (octamer-binding transcription factor
4) and NANOG genes known to be critically involved in self-
renewal of embryonic stem cells [68].
While testing other sarcoma-inducing fusion genes,
only FUS-CHOP-expressing transfected cells were found to
generate tumors resembling human myxoid LPS. Together
with the ﬁndings in ES, these data raise the intriguing pos-
sibility that ES and MLS may originate from closely related
mesenchymal cells, but at diﬀerent anatomical locations.
Perhaps the microenvironment (bone in ES, soft tissue in
MLS) contributes to the line of diﬀerentiation that the MSC
follow according to the adaptability of the transformed cell
to survive in a given tissue environment [69].Sarcoma 9
2.13. Mesenchymal-Epithelial Transition in Sarcoma. Anoth-
er puzzling and intriguing feature of certain sarcomas is the
apparentspontaneoustransitionfromamesenchymaltumor
to an epithelial enriched tumor (mesenchymal-epithelial
transition (MET)). There is growing evidence supporting
the role of epithelial-to-mesenchymal transition (EMT)
during carcinoma progression and metastases linked to the
consequences in cell morphology, cell-to-cell adhesion, cell
motility, and plasticity to migrate and growth in the extra-
cellular matrix. The mesenchymal to epithelial transition
(MET) in sarcoma progression is considerably less well
studied. Triggering of MET has been shown to be induced by
c-met proto-oncogene, a TK receptor for HGF/SF. Increased
expression of this protein leads to epithelial diﬀerentiation.
Epigenetic regulation of DNA methylation has also been
related to the MET [70].
This phenomenon is particularly notable in SS.
Monophasic SS is entirely composed of spindle cells
with or without solid epithelial areas, whereas the biphasic
SS contains a lining of epithelial cells amongst the spindle
cells [71]. At a molecular level, the SYT-SSX1 fusion
occurs ﬁve times more frequently in biphasic SS exhibiting
MET in comparison to SYT-SSX2 in monophasic SS.
These data indicates a possible role of SYS-SSX1 and
SYT-SSX2 in the MET phenomenon by interacting with
transcription receptors (snail or slug, resp.) interfering
with the E-cadherin gene and triggering the MET epithelial
diﬀerentiation program in the aﬀected SS cells [72].
Similar observations have been described in a chon-
drosarcoma model, where upregulation of 4 distinct epithe-
lialmarkersandthedownregulationofsnailwerefound.Loss
of DNA methylation was demonstrated in maspin and 14-3-
3σ genes leading to increased expression of these 2 epithelial-
speciﬁc genes during chondrosarcoma genesis. These results
support the relationship between MET and an epigenetic
switch in chondrosarcoma [73].
2.14. MicroRNA in Sarcomas. The discovery of microRNA
(miRNA) has been one further step into the molecular
universeofgeneregulationandcellbiologyandconsequently
into the biology of cancer cells and oncogenesis. There is
an intense search for miRNA proﬁles in diverse human
cancers to better understand the role of these minute
RNA molecules in cancer control and to explore potential
therapeutic implications [74].
Preliminary work in sarcomas has disclosed unique
miRNA expression signatures according to the histological
types seemingly reﬂecting the cell lineage and diﬀerentiation
status of the tumors [75]. Hierarchal clustering of 87
miRNAs disclosed four main groups, whereby almost all
SS, RMS, LMS, and GIST were grouped distinctively. In
GIST, miR-221 and miR-222 had low expression, suggesting
that the decreased suppressive activity of these miRNAs
allows increased translation of KIT. The miRNAs that play a
major role in myogenesis, miR-1, miR-133A, and miR-133B,
were overrepresented in LMS, whereas miR-335, involved in
skeletal muscle diﬀerentiation, was present in ARMS. In SS,
miR-143 whose target is ERK5 (MAPK7), was expressed at
very low levels suggesting that this miRNA may be involved
in the expression of the SYT-SSX1 oncoprotein [76]. Others
have linked the expression of miR-200 to mesenchymal-
epithelial diﬀerentiation often reported in SS [77].
In a recent study exploring the genesis of CSC phenotype
in ES, Riggi and collaborators [78] published evidence that
repression of miRNA-145 and expression of the EWS-FLI-1
fusion gene were both necessary to induce transformation.
They showed evidence that their common target may be the
SOX2 gene. This gene is known to code for transcription
factors required for the development of pluripotent stem
cells. These observations provided valuable insight into the
mechanisms, whereby a single oncogene (EWS-FLI1) can
reprogram cells towards CSC.
3. Therapeutic Implications
Targeting the multiple molecular pathways and mechanisms
summarized above is one of the areas of intense basic and
clinical research. The objective is to ﬁnd means to modify
tumor behavior and to ﬁnd long awaited clinical therapeutic
options forthesepatients.Searchforantagonisticantibodies,
TKinhibitors,andinhibitorsofdownstreammoleculesofthe
PI3K, MAPK, and mTOR paths are at the forefront of these
eﬀorts (Figure 2). The preliminary clinical trials have not
yet crystallized into therapeutic breakthroughs despite solid
preclinical evidence, suggesting a broad range of favorable
biological eﬀects from the inhibition of these pathways.
3.1. IGF-1R Antibodies. Preclinical data proves that eﬀective
blockade of IGF-1 and IGFII ligands to the IGF-1R is feasible
[79]. Monoclonal antibodies against the IGF-1R have been
the favored approach to date. Phase I and II studies of IGF1R
antagonists ﬁgitumumab, cixutumumab, AMG479, R1507,
and SCH 717454 either alone or in combination with other
agents, are currently under clinical investigation for patients
with sarcomas. Table 5 summarizes the results of reported
phase I/II studies with anti-IGF-R1 agent [79–83].
Further, IGF-1R has been implicated in chemotherapy
resistance from in vitro work with malignant cells. In an
ES tumor model, combination of ADW742 with imatinib,
vincristine, and doxorubicin induced a signiﬁcant reduction
of tumor cell growth, mainly by increasing apoptosis [84].
Similarly, NVP-AEW541 led to cytotoxicity and induced
apoptosis in imatinib resistant or wildtype GIST [85].
Finally, there is experimental evidence that bidirectional
crosstalk between the IGF system and the erbB family of
receptors may confer means of escape or resistance to target
therapy of these receptor pathways [51]. Thus, the use
of combined therapies aiming to block several pathways
simultaneously is being actively investigated in various
tumors.
3.2. TKs Inhibitors and Antiangiogenesis. As described above,
TKs account for a large number of defective signaling
pathways in sarcomas. Based on the success of imatinib in
GIST, TKs inhibitors are of major interest in other sarcomas.
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Table 5: Current Anti-IGF treatment of sarcomas.
Monoclonal antibodies Human trials Disease control rate
(CR, PR, and SD) Comments
Figitumumab CP-751, 871 ES/STS 10/28 (35%) Anti-IGF-IR
Cixutumumab STS 22/37 (59%) Liposarcomas; block hybrid
receptors
Robatumumab SCH 717454 Preclinical OS, RMS Anti-IGF-IR
Ganitumab AMG479 ES 2/15 (13%)
RI 507 ES 18/125 (14.4%) No SD included
TK inhibitors Status Target disease
NVP-AEW541 Preclinical ES/STS/GIST Synergy with chemoRx
NVP-ADW 742 Preclinical ES Synergy with imatinib
BMS-536924 Preclinical STS ATP-competitive IGF-IR
Others Status Target disease
Nordihydroguaiaretic acid (NDGA) Preclinical STS Disrupts IGF-1R; blocks HER-2
GISTs [86]. Patients with chordomas, desmoids, and DFSP
tumors reportedly responded to imatinib in small trials and
isolated case reports, likely via inhibition of PDGFR [87].
Initial attempts intended to block signaling pathways
with other available agents known to interfere with either
cellularreceptorsorTKshavenotmetwithevidenceofmajor
or consistent clinical beneﬁt. Phase II studies with EGFR
inhibitors (geﬁtinib or erlotinib) showed no clinical activity
in SS or malignant nerve-sheath tumors. Use of trastuzumab
in ES and OS, alone or in combination with chemotherapy,
has had no therapeutic beneﬁt. Phase II studies with
sunitinib in non-GIST sarcomas have only shown occasional
objective responses, but disease stabilization over 12 weeks
was noted in several histologies [87]. Sorafenib, but not
sunitinib, was reported to produced a 14% PR rate and a
median OS of 14.3 months in angiosarcomas [88]. SomeSarcoma 11
Table 6: Current clinical trials with tyrosine kinase inhibitors in sarcomas.
Agent Human trials Clinical beneﬁt rate (CR, PR, and SD) Targets: notes
Imatinib GIST 85% (5% CR; 45% PR) KIT. FDA Approved
Sunitinib GIST 65% (7% PR) VEGFR-1, VEGFR-2, VEGFR-3, PDGFR a/β,K I T .
FDA Approved
Sorafenib Angiosarcoma, GIST 14% VEGFR-2, VEGFR-3, PDGFR, c-RAS, b-RAF, KIT
Pazopanib Palette
STS PFS = 20 versus 7 weeks (P = 0.0001) VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β,K I T
Brivanib STS
ASCO 2011
30% overall
3 PR in angiosarcomas
FGF and VEGF
(FGF-positive did better)
Cediranib STS
ASCO 2011
78% (43%, PR)
A l v e o l a rs o f tp a r ts a r c o m a VEGFR-1, VEGFR-2, and VEGFR-3
Tivantinib STS
ASCO 2011
80% (5%, PR)
Clear cell sarcoma, ASPS c-Met
Axitinib STS, angiosarcoma N/A VEGFR-1, VEGFR-2, and VEGFR-3
Table 7: Current clinical trials with rapalogs in sarcomas.
Agent Human trials Clinical beneﬁt rate (CR, PR, and SD) Notes
Temsirolimus GIST
ASCO 2010
GIST = 4/15 (27%)
STS = 2/15 (13%) Refractory GIST
Temsirolimus Phase II STS
Mayo Clinic 5%
Sirolimus Kaposi sarcoma 15/15 (100%) Posttransplant KS
Dermal lesions
Ridaforolimus Phase II-STS 61/212 (29%; 2% PR) IV formulation
Ridaforolimus SUCEED trial PFS: HR = 0.69 (P<0.0001) (22.4 versus 14.7 weeks) Maintenance after ChemoRX
sarcoma subtypes with a predominant vascular connective
tissue component such as angiosarcomas, intimal sarcomas,
and hemangiopericytomas may arise from endothelial cells,
suggesting that proangiogenic proteins may be relevant
to their growth and potential treatment targets. Several
multitargeted receptor TK inhibitors with antiangiogenic
eﬀectsarecurrentlyonclinicaltrials.Table 6 showspublished
or reported data on various new multitargeted TKs [89–93].
ABT-510, a peptide that mimics the antiangiogenic
activityofthrombospondin-1, wastestedinaphaseIItrialin
patients with advanced STS. Approximately 50% of patients
achieved SD, with 1 objective response. Perifosine an AKT
inhibitor has been tested in phase I and phase II trials
in patients with advanced STS with inconsistent results.
No objective responses were observed but 27% of patients
experienced SD in one study with a 5% PR rate and 45%
of patients experienced SD for >4 months in a retrospective
evaluation [94].
3.3. mTOR Inhibitors. The clinical impact of analogs of
rapamycin (rapalogs) in the management of renal cell
carcinoma has conﬁrmed the antitumor potential of mTOR
pathway interference [95]. The participation of mTOR in the
genesis of sarcoma is related to the primordial role of the
IGF system in these tumors. Thus, mTOR inhibitors were a
natural choice to test clinically in sarcomas.
Rapamycin exert its biological eﬀects by forming a
complex with FKBP12 which binds to the FK-rapamycin
binding domain of mTOR inhibiting the function of
mTORC1-mediated signal pathway and resulting in a direct
antiangiogenic eﬀect [58]. A number of preclinical studies
with various rapalogs paved the way to subsequent human
trials. These have included in vitro and in vivo observations
in mouse xenograft models using sirolimus, temsirolimus,
everolimus, and ridaforolimus. Of relevance, temsirolimus
inhibitsHIF-1αtranslationandinterfereswithVEGFprotein
expression in RMS demonstrating suppressed tumor growth
via anti-angiogenesis [96]. Other models have suggested
that sarcomas associated with PTEN loss or inactivation
may be particularly susceptible to the therapeutic eﬀects
of mTOR inhibitors [58, 59]. Rapalogs have been shown
to be less eﬀective or ineﬀective in the presence of KRas
mutations or overexpression of Bcl2, whereas tumors with
cyclin D1 expression and “angiogenesis addiction” are more
susceptible [97].
Phase I/II clinical trials with several rapalogs and com-
binations aim to determine eﬃcacy in sarcoma patients.
Ongoing studies include testing eﬃcacy of sirolimus in KS,
temsirolimus, and valproic acid in OS and STS; or combina-
tions with vinorelbine for uterine sarcoma, liposomal dox-
orubicin or irinotecan for recurrent or refractory sarcomas
[96, 97].Table 7 summarizes data on early phase studies with
rapalogs. Ridaforolimus is a nonprodrug rapalog that has
shown promising clinical activity in STS [98, 99]. Despite
disputed clinical impact (the diﬀerence in median PFS was
only 3 weeks), this drug is awaiting approval in 23 countries
including the FDA in the US based on these studies.12 Sarcoma
3.4. Combinatorial Studies. A number of early clinical
studies explored combination of agents intended to block
redundant or cross-talking molecular pathways or to cir-
cumvent chemotherapy resistance. These include everolimus
with imatinib, phase II study in imatinib-resistant GIST;
everolimus and ﬁgitumumab; temsirolimus with cixutu-
mumab in ES (65% of patients had tumor reduction >20%)
ridaforolimus and doxorubicin; everolimus and pegylated
liposomal doxorubicin, mTOR inhibitors and hormonother-
apy, and many others will follow [96–99]. There is also a
growing interest in the use of other agents including mela-
tonin, metformin, celecoxib, statins, and others which have
been shown to modulate molecular signals in the pathways
involvedintumorgrowth.Melatoninhasbeenshowntohave
a broad range of activities resulting in an oncostatic eﬀect
in vitro and in vivo including suppression of tumorigenesis
in methylcholanthracene-induced ﬁbrosarcomas in mice
[100]. In an ES in vitro model, melatonin has been shown
to induce apoptosis and synergism when combined with
chemotherapeutic agents [101]. Metformin reduces insulin
level by decreasing insulin resistance a favorable eﬀect on
cancercellsdependent on theIGF system.Adirect inhibitory
eﬀect of metformin on cancer cell growth has also been
reported and has been associated to a regulatory role in the
AMP-activated protein kinase (AMPK) and mTOR pathways
[102].
4. Conclusions
A wealth of information is accumulating at a rapid pace
that, undoubtedly, will continue to contribute to the further
understanding of the molecular biology of sarcomas. There
are, however, enormous challenges ahead, particularly in
the clinical translation of these discoveries. Despite the
success noted in KS and the success of imatinib treatment
in GIST, only modest gains have been attained in our
attempts to alter or modulate growth of tumor in most
other sarcomas. It is clear that the rarity of this vast number
of pathological entities complicates the clinical application
of the newly developing agents. But the existence of fairly
speciﬁc genetic abnormalities, mainly speciﬁc translocations
and a generation of discernible fusion genes in various
sarcomas make research in these tumors an attractive mold
for advancing studies of solid tumors.
Findingkeymolecular“nodes”orpathwaysthatarecom-
mon amongst these tumors will help to further understand
the pathogenesis of sarcomas and may help improve current
therapeutic choices. Yet, the redundancy of these molecular
cascades, the loopholes and the fact that tumors may ﬁnd
adaptive escape routes necessitate incessant search for deeper
understanding of the signaling pathways in the context of
all the hallmarks of cancer discussed above. The concept
of system biology and the development of computational
and mathematical models are areas that will facilitate the
organization of thoughts directing future research strategies.
Clinically, biologic eﬀects are largely cytostatic and
transient which indicate the need to devise new strategies to
reachlong-termclinicalcontrolandpotentialcureofsomeof
these entities. Newer clinical trials are beginning to modify
the chemotherapy-oriented criteria of response and criteria
in the designing of clinical studies [103]. Emphasis is being
placed in the selection of patient populations to avoid the
pitfalls of unselected trials that have often missed the target
inthepast.Thereis acleartrendtoconsiderprogression-free
survival (PFS) as a more relevant endpoint when assessing
the antitumor eﬀects of molecular targeted therapies. It has
been suggested that ﬁrst-line treatments should achieve PFS
rates of >30% at 6 months for the results to be considered
clinically meaningful in phase II trials in STS [86].
Assessment of “metabolic” response by FDG-PET is
being examined as a better mean of assessing antitumor
activity of targeted therapies as opposed to traditional
RECIST-deﬁned responses. Support for this is coming in
many ﬁelds including sarcoma trials [104]. FDG-PET has
been shown superior to CT in predicting early response and
monitoring of response and progression to imatinib therapy
in GIST and other STS [105, 106]. Furthermore, FDG-PET
may also have applicability as an early pharmacodynamic
marker of molecular targeted therapies [106].
Although the concept of “personalized” therapy has been
overestimated there is clearly a need to continue searching
for uniqueness among subgroups of patients, particularly
in sarcomas, this most heterogeneous collection of diseases.
Cardinal to these eﬀorts is the search for molecular markers
that identify patients most likely to beneﬁt from a given
intervention as well as to monitor the biological eﬀects
of the treatment or to identify the optimal dose of these
agents. It is necessary to dismiss the chemotherapy-driven
concept of maximum tolerated dose and ﬁnd instead the
optimal biologic dose of the agents being tested. So far
the identiﬁcation of clinically relevant molecular markers
has been daunting but progress in the area is expected
as methodologies to examine eﬃciently multitude putative
“markers of interest” are developed.
These interventions are not strictly tumor-speciﬁc and
elicit cellular and clinical toxicity and may hamper our
enthusiasm to some extent as we have already witnessed in
other ﬁelds including RCC, melanoma, colon, breast, and
other cancers. The identiﬁcation of more precise targets and
reﬁnement of the speciﬁcity of targeted agents is required
to make progress in this ﬁeld. These targets should be
those that are essential for the malignant cells to subsist, a
conceptthathasbeentermed“oncogeneaddiction.”Buteven
well-characterized mutations can have diﬀerent molecular
isoforms that could alter the speciﬁcity and durability of
the binding to the therapeutic agent or render the agent
less eﬃcacious. Identiﬁcation of precise “pockets” within
the abnormal targeted molecule may also improve the
therapeutic index of future targeted therapies.
Enormous clinical challenges lie ahead, but a new world
of possibilities is opening. Combination strategies are very
attractive because of the multitude of potential targets and
because of the diﬀerent properties and mechanisms of action
of drugs in our growing arsenal. However, the combination
of some of these agents has already shown additive toxicities
withoutanadditionalantitumoreﬀect.Antagonismhasbeen
observed in some combinations that seemed logical andSarcoma 13
promising and, although observed in preclinical models, we
are yet to prove synergism when combining these agents.
Combination therapies should not be limited to molecular-
targeted drugs as we can judiciously combine these with
chemotherapeutic agents. Furthermore, these combination
strategies must include eﬀorts to modulate the microenvi-
ronment of the tumorand the immune systemtoattain a full
and comprehensive approach to the control of the malignant
growth in sarcomas and other cancers.
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